Thomas fabre
Senior Principal Scientist Pfizer
Seminars
Wednesday 2nd December 2026
Building Cross-Tissue Fibrosis Atlases to Identify Conserved Pathogenic Cell States & New Therapeutic Targets
11:00 am
- Integrating single-cell and spatial datasets across lung, liver, kidney, joint, gut, skin, and other fibrotic tissues
- Identifying conserved macrophage states that persist across organs to distinguish truly pan-fibrotic mechanisms from tissue-specific biology
- Using cross-tissue atlases to prioritize targets, select the most relevant disease indications, and match mechanisms with fit-for-purpose translational models
Thursday 3rd December 2026
Fireside Chat: Moving Beyond Slowing Fibrosis to Define the Biology, Data & Trial Designs Needed to Stop or Reverse Disease to Deliver Meaningful Patient Benefit
10:00 am
- Reflecting on the discoveries that have enabled antifibrotic therapies to slow disease progression, and debating whether these same insights are sufficient to guide therapies that stop or reverse fibrosis
- Defining what true fibrosis regression means, including ECM remodeling, fibrinolysis, fibroblast deactivation, restored tissue architecture and functional recovery
- Determining whether different cell types, molecular mechanisms, datasets, biomarkers, and clinical trial designs are needed to distinguish therapies that slow progression from those that actively reverse fibrotic disease
